IMMUGENICS AG has a total of 16 patent applications. Its first patent ever was published in 1999. It filed its patents most often in WIPO (World Intellectual Property Organization), Australia and Canada. Its main competitors in its focus markets pharmaceuticals and biotechnology are AVIPEP PTY LTD, ARP BIOMED LTD and PINCELL SRL.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 4 | |
#2 | Australia | 3 | |
#3 | Canada | 3 | |
#4 | EPO (European Patent Office) | 3 | |
#5 | Germany | 2 | |
#6 | New Zealand | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Theobald Matthias | 11 |
#2 | Stanislawski Thomas | 8 |
#3 | Voss Holger | 5 |
#4 | Lotz Carina | 3 |
#5 | Cellary Anne | 3 |
#6 | Schmitz Frank | 3 |
#7 | Gao Liquan | 2 |
#8 | Theobalt Matthias | 2 |
#9 | Stauss Hans Josef | 2 |
#10 | Thoebald Matthias | 1 |
Publication | Filing date | Title |
---|---|---|
WO02070553A1 | Tumour peptide antigen produced from human mdm2 proto-oncogene | |
WO02070556A1 | POLYPEPTIDE OF A P53 PROTEIN-SPECIFIC MURINE Α/β T-CELL RECEPTOR, NUCLEIC ACIDS CODING THEREFOR AND USE THEREOF | |
EP1363942A2 | Polypeptide from a hdm2 protein specific murine alpha/beta t-cell receptors, nucleic acids coding for the above and use thereof | |
DE10163755A1 | Tumor peptide antigens from human CD19 protein | |
DE10148236A1 | Tumor peptide antigens from human PRDI-BF1 protein |